CorInsights MRI

by ADM Diagnostics  · Based in United States → — See clearly what IMAGING INSIGHTS can reveal for patient care
Geriatrics Neurology Radiology

Contact vendor
Regulatory Status Disclosed

Overview

CorInsights MRI is an FDA-cleared medical image processing software developed by ADM Diagnostics, Inc. It provides quantitative information about brain tissue volume using standard T1-weighted MRI scans. The software measures brain volumes, determines percentiles compared to age- and sex-matched normative values, and identifies patterns of tissue volume loss. This information is translated into a set of images, graphs, and summaries in an illustrated patient-specific report, aiding radiologists, neurologists, and clinical researchers in assessing neurodegenerative conditions like Alzheimer’s disease and other dementias. The analysis is completed securely with a same-day turnaround. CorInsights MRI is intended for adults aged 45 to 95. The product was developed and validated using a curated database of more than 30,000 well-characterized brain images.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Key Features

  • Automated MRI brain image processing
  • Quantitative brain volume measurement
  • Comparison to age- and sex-matched normative data
  • Generation of annotated images and volumetric reports
  • Support for adults aged 45 to 95
  • Secure electronic submission of scans
  • Same-day turnaround for analysis and reports
  • Identification of lowest percentile brain regions
  • Patient-friendly graphs for communication
  • Requires only a T1-weighted MRI scan

Use Cases

  • Aiding in the assessment of Alzheimer's disease
  • Diagnosing and monitoring other neurodegenerative diseases
  • Differentiating various forms of dementia
  • Predicting cognitive decline
  • Measuring treatment effect in clinical trials
  • Providing quantitative visualization for radiologists

What Physicians Need to Know

Brain MRI Analysis
CorInsights MRI is FDA-cleared software that analyzes standard T1-weighted MRI scans to measure brain tissue volumes. It compares these measurements to a proprietary normative database to assist in the diagnosis and monitoring of neurodegenerative diseases.
Neurodegenerative Disease Screening
A primary function is to provide quantitative brain tissue volume measurements, aiding in the assessment of neurodegenerative conditions such as Alzheimer's disease and other dementias. It identifies patterns of volume loss in specific brain regions compared to age- and sex-matched normative references.
Triage Prioritization Speed
The software offers a same-day turnaround for results, providing timely quantitative reports to medical professionals.
Physician Tip

CorInsights MRI provides quantitative visualization of individual brain structures and patterns of affected volumes, integrating efficiently into radiology workflows. It offers clarity and increased confidence for medical professionals in assessing neurodegeneration and provides patient-friendly graphs to convey findings effectively, supporting earlier and more accurate diagnoses.

CorInsights MRI is designed for easy integration into both clinical practice and clinical trials. It supports integration with existing EHR (Electronic Health Record) systems and PACS (Picture Archiving and Communication Systems).

Details

Category Neurology AI, Radiology & Imaging AI
Pricing Contact vendor — Subscription-based
DeploymentSaaS
Compliance
BAA AvailableUnknown AI-estimated
HIPAA CompliantUnknown AI-estimated
FDA Status 1 AI-estimated

CorInsights MRI received 510(k) FDA clearance (K193287) on November 20, 2020. It is classified as Medical Image Processing Software (21 CFR 892.2050) and is intended for automatic labeling, visualization, and volumetric quantification of segmentable brain structures from MR images, with volumetric measurements compared to reference percentile data for adults aged 45 to 95.

Integrations
EHR Not specified
Specialties Geriatrics, Neurology, Radiology

What the Web Says

CorInsights MRI is an FDA-cleared diagnostic report that provides quantitative insights into brain volumes using standard T1-weighted MRI scans. It compares individual brain volumes to an age- and sex-matched normative reference to identify regions with reduced volume, aiding medical professionals in the assessment of neurodegenerative conditions like Alzheimer's disease. Physicians, including neurologists and gerontologists, have expressed a need for such a tool and find the reports excellent and easy to understand, believing it will help with earlier and more accurate diagnoses.

Overall: Positive

Strengths

  • Provides exceptional insights into brain volumes using standard MRI scans.
  • Aids in earlier and more accurate diagnosis of neurodegenerative diseases.
  • Reports are excellent, easy to understand, and patient-friendly.
  • Quantifies brain regions with reduced volume compared to normative data.
  • Requires only a standard T1-weighted MRI scan.
  • FDA-cleared diagnostic report with extensive validation.

Limitations

  • No specific cons were found for CorInsights MRI in the provided search results.
  • Some general concerns about AI in healthcare include potential for errors and the need for human review.
  • Privacy concerns exist with uploading medical data to online AI tools.

Based on reviews from: ADM Diagnostics, HealthAidb, accessdata.fda.gov, GLOBE NEWSWIRE, News - ADMdx, Reddit

Last updated: 2026-07-17

Ratings & Reviews

No reviews yet. Be the first to review this tool!

Rate CorInsights MRI

Clinical Value
Ease of Use
Integration
Support & Docs
Value for Money

Press & Coverage

ADM Diagnostics
ADM Diagnostics, Inc. Announces Receipt of 510(k) FDA Clearance for its CorInsightsu00ae MRI Product
ADM Diagnostics received FDA 510(k) clearance for CorInsights MRI, a product that provides quantitative brain tissue volume information from standard MRI scans to aid in assessing cognitive impairment and neurodegenerative diseases.
2021-12
GlobeNewswire
ADM Diagnostics, Inc. Announces Launch of CorInsightsu00ae MRI
ADM Diagnostics announced the launch of its FDA-cleared CorInsights MRI, which uses proprietary software to analyze standard MRI scans and provide quantitative brain tissue volume measurements for medical professionals.
2021-12
AuntMinnie.com
ADM Diagnostics wins FDA clearance for CorInsights MRI
ADM Diagnostics secured FDA clearance for its CorInsights MRI brain image analysis software, which analyzes standard MRI exams to provide quantitative information about brain tissue volume.
2021-12
Brain Communications (Oxford Academic)
Plasma p-tau217 and glucose metabolism correlate in neocortical association areas in Alzheimer's disease | Brain Communications | Oxford Academic
A study published in Brain Communications utilized ADM Diagnostics' CorInsights MRIu00ae analysis tool for segmenting MRI scans to produce regional z-scores, exploring relationships between plasma biomarkers, FDG-PET, and regional brain volumes in Alzheimer's disease patients.
2026-03
ADM Diagnostics
ADM Diagnostics, Inc. Awarded $1.96 Million Grant From the National Institutes of Health
ADM Diagnostics was awarded a $1.96 million Phase II SBIR grant from the National Institutes of Aging to develop a diagnostic test to detect and differentiate the effects of repeated head impact from Alzheimer's disease, leveraging AI methods and their proprietary database.
2022-09
HealthAidb
CorInsights MRI - HealthAidb u2014 Software
CorInsights MRI is an FDA-cleared software from ADM Diagnostics that analyzes standard MRI scans to provide quantitative brain tissue volume measurements, assisting in the assessment of neurodegenerative conditions like Alzheimer's disease.
2025-10
PMC (PubMed Central)
Technical and clinical validation of commercial automated volumetric MRI tools for dementia diagnosisu2014a systematic review - PMC
This systematic review, published in European Radiology, mentions CorInsights MRI by ADM Diagnostics as one of several commercial quantitative volumetric reporting tools for dementia diagnosis, noting the need for more published clinical validation.
2021-09
accessdata.fda.gov
November 20, 2020 ADM Diagnostics, Inc. Robin Martin Co-Founder, Regulatory Strategist Kinetic Compliance Solutions, LLC PO - accessdata.fda.gov
This FDA document details the 510(k) premarket notification for CorInsights MRI, outlining its intended use for automatic labeling, visualization, and volumetric quantification of brain structures from MR images for adults aged 45 to 95.
2020-11

Videos

Product demos, reviews, and walkthroughs for CorInsights MRI.

View all on YouTube

Frequently Asked Questions

CorInsights MRI seamlessly integrates with your PACS and EMR systems, providing AI-powered analysis that augments your current workflow. It offers benefits such as improved diagnostic accuracy by identifying subtle patterns, increased efficiency through automated measurements, and personalized insights for tailored treatment plans.
CorInsights MRI holds relevant regulatory approvals, such as FDA clearance, for its intended diagnostic use. We ensure HIPAA compliance through robust technical and administrative safeguards, including end-to-end encryption of all Protected Health Information (PHI), strict access controls, and comprehensive Business Associate Agreements (BAAs) with all partners.
CorInsights MRI offers enhanced speed and consistency compared to traditional manual interpretation, reducing human error and fatigue by automating routine tasks and flagging critical findings. While other AI tools exist, CorInsights leverages advanced algorithms for superior pattern recognition and quantitative analysis, aiming to provide more comprehensive and actionable insights.
CorInsights MRI typically operates on a subscription-based licensing model, with pricing varying based on the scale of deployment and specific features required. Initial costs may include integration with existing hospital systems, comprehensive staff training, and ongoing maintenance and support fees to ensure optimal performance and updates.
Like all AI, CorInsights MRI's algorithms may exhibit biases if trained on datasets lacking diversity, potentially affecting accuracy across different demographic groups. Its recommendations should be interpreted with caution in rare or atypical cases, or when findings contradict clinical context, always requiring physician oversight to prevent automation bias.
Patient data processed by CorInsights MRI is secured using industry-leading encryption protocols, both in transit and at rest, within a highly protected infrastructure. Access is strictly controlled through role-based authentication, and all data interactions are meticulously logged and regularly audited to ensure compliance and detect any unauthorized activity.
CorInsights MRI has undergone rigorous internal and external clinical validation studies, demonstrating high accuracy in various diagnostic tasks. Our published data reports strong performance metrics, including specific sensitivity and specificity values, and Area Under the Curve (AUC) scores, which are continuously monitored through real-world performance assessments.

Related Tools

Cercare Medical Oncology Virtual Expert
Cercare Medical
Neurology AI
Cercare Medical's Oncology Virtual Expert is an AI-powered brain tumor segmentation module that provides fast, consistent, and semi-automated tumor analysis from standard MRI data, designed for on-premise deployment within existing clinical radiology workflows.
CoLumbo C-Spine
Smart Soft Healthcare AD
Clinical Decision Support & Reference
CoLumbo C-Spine is an AI-powered software that processes and analyzes cervical spine MRI exams, assisting clinicians in diagnosis and assessment.
MeRT System
Wave Neuroscience
Mental & Behavioral Health AI
MeRT (Magnetic e-Resonance Therapy) is an advanced, personalized form of TMS that uses your own brainwave data to guide treatment. It's a non-invasive, drug-free option designed to help the brain communicate more efficiently so symptoms of conditions like depression, anxiety, PTSD, TBI, autism, and more can improve.
Brainomix 360 Hyperdensity
Brainomix Limited
Neurology AI
Brainomix 360 Hyperdensity is an AI-powered neuroimaging software tool that detects and quantifies brain hyperdensities on CT scans, forming a crucial part of the Brainomix 360 Stroke platform for rapid and accurate stroke assessment.
SOMNUM
HoneyNaps
Clinical Decision Support & Reference
SOMNUM is an AI-enabled medical software tool by Honeynaps Co., Ltd. that provides comprehensive sleep analysis to aid in the diagnosis and management of sleep disorders.
DETECT-ME/CFS project
DETECT-ME/CFS project (ME/CFS Research Foundation)
Clinical Decision Support & Reference
The DETECT-ME/CFS project is developing an AI-supported clinical decision support system to improve the rapid and reliable diagnosis of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.

See all Neurology AI tools →

Suggest an Edit → | Last Verified: 2026-04-17 | First Added: 2026-04-17
AI Tool Finder
AI-powered search. Results may not be comprehensive.